Pentostatin
- Atc Codes:L01XX08
- CAS Codes:53910-25-1
- PHARMGKB ID:53910-25-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
France: Nipent; Germany: Nipent; Greece: Nipent; Ireland: Nipent; Italy: Nipent; Netherlands: Nipent; Portugal: Nipent; Spain: Nipent; UK: Nipent.
North America
USA: Pentostatin, Nipent.
Asia
Japan: Nipent.
Drug combinations
Chemistry
Pentostatin: C~11~H~16~N~4~O~4~. Mw: 268.27. (1) Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)-; (2)(R)-3-(2-Deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol. CAS-53910-25-1 (1977).
Pharmacologic Category
Other Antineoplastic Agents. Antimetabolite; Purine Antagonist. (ATC-Code: L01XX08).
Mechanism of action
A purine antimetabolite which inhibits adenosine deaminase, preventing deamination of adenosine to inosine. Accumulation of deoxyadenosine and deoxyadenosine 5′-triphosphate results in reduction of purine metabolism and DNA synthesis and cell death.
Therapeutic use
Treatment of hairy cell leukemia.
Pregnancy and lactiation implications
Animal studies demonstrated teratogenicity, maternal toxicity, and fetal loss. There are no adequate, well-controlled studies in pregnant women. Not recommended during lactation.
Unlabeled use
Treatment of cutaneous T-cell lymphoma, chronic lymphocytic leukemia, and acute and chronic graft-vs-host disease.
Contraindications
Hypersensitivity to pentostatin or any component of the formulation.
Warnings and precautions
Hazardous agent. Bone marrow suppression may occur. Severe CNS toxicities, severe liver/renal toxicities, and severe pulmonary toxicities occurred with doses higher than recommended. Should not be administered concurrently with fludarabine. Severe rashes may occur. Infections should be resolved, if possible, prior to initiation of treatment. Use with caution in renal dysfunction (CrCl <60 mL/minute). Fatal pulmonary edema and hypotension reported in patients treated with pentostatin in combination with carmustine, etoposide, or high-dose cyclophosphamide as part of myeloablative regimen for bone marrow transplant.